July 2023 in “Australasian Journal of Dermatology” This study described the incidence and prevalence of alopecia areata in Australia's primary healthcare population, finding the highest incidence in individuals aged 19 to 34, with males more affected than females.
3 citations
,
March 2023 in “Journal of Medical Economics” This study found that middle-aged patients, patients in certain geographical regions, and female patients of specific age groups with alopecia areata face higher medical costs, indicating significant financial variability for affected subgroups.
6 citations
,
July 2022 in “Journal of health economics and outcomes research” This study found that US adolescents with alopecia areata, especially those with alopecia totalis or universalis, experience significantly higher healthcare costs and resource use compared to matched controls.
12 citations
,
April 2022 in “Dermatology and therapy” This study reports that patients with alopecia areata in the US incur significantly higher healthcare utilization and expenses, primarily driven by ambulatory and pharmacy costs, compared to matched controls.
4 citations
,
March 2022 in “Dermatology and Therapy” This study found that alopecia areata severity significantly influences the health-related quality of life impacts and treatment patterns among affected individuals.
20 citations
,
February 2022 in “British Journal of Dermatology” This study found that people with alopecia areata have higher rates of depression and anxiety, leading to increased mental health treatment burden, more time off work, and higher unemployment compared to the general population.
11 citations
,
November 2021 in “BMJ Open” This study reviews the epidemiology of alopecia areata in the UK, focusing on its links to mental health comorbidities, autoimmune/atopic associations, and common infection incidences.
23 citations
,
July 2021 in “Advances in Therapy” This study observed that patients with alopecia areata often have comorbidities and experience significant healthcare costs, with treatments like systemic therapies being infrequently used.
117 citations
,
July 2021 in “British Journal of Dermatology” This study reports that the incidence of alopecia areata is 0.26 per 1000 person-years in the UK, with higher rates among Asian ethnic groups, socially deprived populations, and urban residents.
100 citations
,
July 2018 in “Journal of The American Academy of Dermatology” This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.
37 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that black and Hispanic women had higher odds of self-reported alopecia areata compared to white women, highlighting potential racial disparities in the condition's occurrence.
95 citations
,
July 2016 in “Journal of The American Academy of Dermatology” This review concluded that patients with alopecia areata consistently show poor health-related quality of life scores, similar to those in other chronic skin diseases like atopic dermatitis and psoriasis.
128 citations
,
February 2016 in “British Journal of Dermatology” This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.
